Promentis Pharmaceuticals: Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting novel Glutamatergic mechanism

Promentis is developing SXC-2023 along with other compounds that engage System xc-, a central nervous system target addressing glutamatergic imbalance and oxidative stress, to treat trichotillomania and otherThe post Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting novel Glutamatergic mechanism appeared first on Pharmaceutical Business review.